Determination of Clinical Characteristics With Immunophenotyping in Large Vessel Vasculitis
In this study, researchers used immunophenotyping to explore the biomarkers associated with clinical characteristics in large vessel vasculitis.
Giant Cell Arteritis
Temporal Ultrasound May Be Useful in Giant Cell Arteritis Disease Monitoring
Researchers suggest that temporal ultrasound may be an appealing choice for monitoring disease activity in patients with cranial giant cell arteritis treated with tocilizumab.
Decrease in Giant Cell Arteritis Relapse Risk With Elevated Platelet Count, CC Promoter Polymorphism
Researchers studied the risk factors for relapse, including prednisolone clearance and glucocorticoid-induced transcript 1 promoter polymorphism (rs37972), in patients with giant cell arteritis.
Survival Predictors Identified in Patients With Biopsy-Proven Giant Cell Arteritis
Researchers evaluated the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of patients with giant cell arteritis.
Color Duplex Sonography for the Diagnosis, Management of Giant Cell Arteritis
The use of color duplex sonography for the diagnosis of patients with suspected giant cell arteritis is associated with high specificity and positive predictive value.
Giant Cell Arteritis Diagnosis in Glucocorticoid-Treated Patients: Utility of PET/CT
The utility of PET and CT imaging to complement temporal artery biopsy in patients with newly diagnosed giant cell arteritis who are receiving glucocorticoid therapy remains equivocal.
FDA Approves First Drug to Specifically Treat Giant Cell Arteritis
Actemra (tocilizumab) has been FDA-approved for its use in giant cell arteritis treatment.
FDA Gives Tocilizumab Priority Review Status for Giant Cell Arteritis
FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.
Increased VTE Risk in GCA With and Without Glucocorticoids
Patients experienced an elevated risk of venous thromboembolism both immediately before and immediately after giant cell arteritis diagnosis.
New-Onset Diabetes Risk in Giant Cell Arteritis With Prednisone
Treatment of giant cell arteritis or granulomatosis with polyangiitis with prednisolone or prednisone has been linked to elevated risks of type 2 diabetes early during treatment.
Next post in Vasculitis
